Other featured articles
The FDA is the Right Agency to Regulate CBD Products, but It Needs Help
Undefined and unregulated, CBD will continue to pose unnecessary risks and never reach its potential as a legitimate health supplement.Posted in
Small Cannabis Producers Have Bigger Problems than State Taxes and Regulation
Removing regulations and taxes on cannabis sales would take away resources that are needed to address legitimate public health concerns and won’t solve the supply-side problem.Posted in
Avoiding Cannabis Chaos: Better Policies and Strategies for a Legal Market
On February 2, join our expert panel as they debate how to better regulate the cannabis market so that consumers are protected and the industry operates on the up-and-up.
The Cannabis Policy Scale: A New Research and Surveillance Tool for U.S. States
USC researchers developed composite measures to characterize the restrictiveness of U.S. state cannabis policy environments.Posted in
OUR WORK IN CANNABIS
Patient Preference for Medical Cannabis Products in the Absence of Clinical Guidelines
New analysis of New York data finds considerable variability in patient product choice, even for patients with the same condition.Categorized in
Spatial and Temporal Trends in the Diagnosis of Opioid-Related Problems in Commercially-Insured Adolescents and Young Adults
USC researchers looked at claims data from privately insured individuals with an opioid-related problem.
Cannabis Regulations Inadequate Given Rising Health Risks of High-Potency Products
A new USC Schaeffer Center white paper shows how state-level cannabis regulations have weak public health parameters compared to other countries, leaving consumers vulnerable.Categorized in
Federal Regulations of Cannabis for Public Health in the United States
State-level cannabis regulations have weak public health parameters compared to other countries, leaving consumers vulnerable.Categorized in
Rating the Comparative Efficacy of State-Level Cannabis Policies on Recreational Cannabis Markets in the United States
Schaeffer experts identified identified key cannabis policies and their provisions enacted by U.S. states; rated their theoretical efficacy in a restrictive form for reducing problematic use and impaired driving in the context of a recreational cannabis market as judged by experts; and rated the strength of evidence for each policy.
Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients
Schaeffer experts estimate the primary care prevalence of medical cannabis use according to confidential patient survey and to compare the prevalence of medical cannabis use documented in the EHR with patient report.